Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
There is no FDA-approved generic version of Ozempic (semaglutide) as of 2026
A 2023 retrospective cohort study found semaglutide significantly reduced binge eating episodes in patients with BED the first study of its kind A 2020 pilot study of dulaglutide found it reduced binge episodes in patients with type 2 diabetes and BED A 2026 meta-analysis found liraglutide reduced binge frequency by approximately 1.28 fewer episodes per week compared to placebo A rapid review of 25 studies encompassing over 8,700 adult patients found that binge eating episodes and prevalence reduced following liraglutide and semaglutide An observational study of 69 people with obesity found emotional eating dropped from 72.5% to 11.5% after three months of semaglutide The Critical Caveats Despite a promising early signal, these findings should be held carefully
A licensed provider reviews your information and conducts a video or phone consultation
Discussion The key findings from the two reported trials were that administration of oral semaglutide in the fed state resulted in limited semaglutide exposure, that semaglutide exposure increased with longer post-dose fasting periods, particularly from 15 to 30 min, and that semaglutide exposure was comparable when the oral semaglutide tablet was administered with 50 or 120 mL water
